Patents by Inventor Susan Acton

Susan Acton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND USES THEREFOR
    Publication number: 20100273989
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostic methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Application
    Filed: December 22, 2008
    Publication date: October 28, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
  • Angiotensin converting enzyme homolog and uses therefor
    Patent number: 7482171
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: January 27, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
  • Novel protein kinase molecules and uses therefor
    Publication number: 20080050840
    Abstract: The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 16, 2007
    Publication date: February 28, 2008
    Inventor: Susan Acton
  • 59079 and 12599, protein kinase family members and uses therefor
    Publication number: 20050255521
    Abstract: The invention provides isolated nucleic acids molecules, designated 59079 and 12599 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 59079 or 12599 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 59079 or 12599 gene has been introduced or disrupted. The invention still further provides isolated 59079 and 12599 proteins, fusion proteins, antigenic peptides and anti-59079 and anti-12599 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 21, 2005
    Publication date: November 17, 2005
    Inventors: Rosana Kapeller-Libermann, Susan Acton
  • Angiotensin converting enzyme homolog and uses therefor
    Publication number: 20050147600
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Application
    Filed: February 16, 2005
    Publication date: July 7, 2005
    Inventors: Susan Acton, Keith Robison, Frank Hsieh
  • Angiotensin converting enzyme homolog and uses therefor
    Patent number: 6884771
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: April 26, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
  • Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
    Publication number: 20050037946
    Abstract: The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 and 2419 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease.
    Type: Application
    Filed: January 8, 2004
    Publication date: February 17, 2005
    Inventors: Nancy Stagliano, Aileen Healy, Susan Acton, Katherine Galvin, Mary Donoghue, Amelie Rodrigue-Way, James Tomlinson
  • Novel protein kinase molecules and uses therefor
    Publication number: 20050027108
    Abstract: The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 25, 2004
    Publication date: February 3, 2005
    Inventor: Susan Acton
  • Novel protein kinase molecules and uses therefor
    Publication number: 20020094559
    Abstract: The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: January 10, 2001
    Publication date: July 18, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Phospholipase molecule and uses therefor
    Patent number: 6268135
    Abstract: Novel CSAPL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPL proteins, the invention further provides isolated CSAPL fusion proteins, antigenic peptides and anti-CSAPL antibodies. The invention also provides CSAPL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: July 31, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • CSAPTP nucleic acid molecules and uses therefor
    Patent number: 6258582
    Abstract: Novel CSAPTP polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPTP proteins, the invention further provides isolated CSAPTP fusion proteins, antigenic peptides and anti-CSAPTP antibodies. The invention also provides CSAPTP nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPTP gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: July 10, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • CSAPK-3 protein and uses therefor
    Patent number: 6214597
    Abstract: The present invention provides a novel protein kinase, CSAPK-3, as well as CSAPK-3 fusion proteins, antigenic peptides and anti-CSAPK-3 antibodies.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: April 10, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Protein kinase molecules and uses therefor
    Patent number: 6200770
    Abstract: The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: March 13, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Methods for identifying compounds that bind to CSAPK-1
    Patent number: 6190874
    Abstract: The present invention provides methods for identifying compounds that bind to CSAPK-1, a cardiovascular system associated protein kinase.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: February 20, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Protein kinase molecules and uses therefor
    Patent number: 6183962
    Abstract: The invention provides isolated nucleic acid molecules, designated CSAPK-1 nucleic acid molecules, which encode novel cardiovascular system associated protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for producing CSAPK-1 polypeptides.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: February 6, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Methods for identifying compounds that bind to CSPAK-2
    Patent number: 6180358
    Abstract: The present invention provides methods for identifying compounds that bind to CSAPK-2, a cardiovascular system associated protein kinase.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: January 30, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • CSAPK-1 protein and uses therefor
    Patent number: 6153417
    Abstract: The present invention provides a novel protein kinase, CSAPK-1, as well as CSAPK-1 fusion proteins, antigenic peptides and anti-CSAPK-1 antibodies.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: November 28, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Protein kinase molecules and uses therefor
    Patent number: 6146832
    Abstract: The invention provides isolated nucleic acid molecules, designated CSAPK-2 nucleic acid molecules, which encode novel cardiovascular system associated protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for producing CSAPK-2 polypeptides.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: November 14, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • Methods for identifying compounds that bind to CSAPK-3 molecules and fragments thereof
    Patent number: 6146841
    Abstract: The present invention provides methods for identifying compounds that bind to CSAPK-3, a cardiovascular system associated protein kinase.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: November 14, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton
  • CSAPK-2 protein and uses therefor
    Patent number: 6121030
    Abstract: The present invention provides a novel protein kinase, CSAPK-2, as well as CSAPK-2 fusion proteins, antigenic peptides and anti-CSAPK-2 antibodies.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: September 19, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Susan Acton